AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21075163 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participants
Number of subjects: 48
Study 19477893 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision support tool
Number of subjects: 200
Study 19477893 — intervention group
Group type: COMPARATOR
Intervention: Verbal narrative alone
Number of subjects: 200
Study 17460095 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 MENT implants
Number of subjects: 29
Study 17460095 — intervention group
Group type: COMPARATOR
Intervention: 600-mg testosterone pellets every 12 weeks
Number of subjects: 29
Study 12749479 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets
Number of subjects: 0
Study 12749479 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11213665 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 58
Study 11213665 — intervention group
Group type: COMPARATOR
Intervention: Light touch protocol (Control)
Number of subjects: 58
Study 8623729 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue-plasminogen activator (t-PA) plus weight-adjusted heparin
Number of subjects: 162
Study 8623729 — intervention group
Group type: COMPARATOR
Intervention: anisoylated plasminogen streptokinase activator complex (APSAC) without heparin
Number of subjects: 162
Study 8623729 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose aspirin (81 mg)
Number of subjects: 162
Study 8623729 — intervention group
Group type: COMPARATOR
Intervention: standard-dose aspirin (325 mg)
Number of subjects: 162
Study 1600973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 22
Study 1600973 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 22
Study 3893132 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electronic intrapartum fetal heart monitoring
Number of subjects: 12964
Study 3893132 — intervention group
Group type: COMPARATOR
Intervention: Intermittent auscultation
Number of subjects: 12964
Study 3893132 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 1 year for babies who survived neonatal seizures
Number of subjects: 12964
Study 30309449 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal aortic calcification (AAC)
Number of subjects: 151
Study 30309449 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe calcification (AAC score ≥ 7)
Number of subjects: 151
Study 30309449 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of AAC
Number of subjects: 151
Study 26975428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue group
Number of subjects: 41
Study 26975428 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 24748783 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained Group (TG) - 8-week flexibility training program, 2 sessions/week, including warm up (10 min), central period (50 min), and cool down (10 min)
Number of subjects: 37
Study 24748783 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained Group (TG) - 8-week flexibility training program
Number of subjects: 37
Study 24748783 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No physical activity during the experimental period
Number of subjects: 37
Study 22810643 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of otinum (choline salicilate)
Number of subjects: 50
Study 22810643 — intervention group
Group type: COMPARATOR
Intervention: 3% alcoholic solution of boric acid (control)
Number of subjects: 50
Study 20502723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 0
Study 20502723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 0
Study 20502723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20502723 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study 18037095 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/d for 6 weeks
Number of subjects: 24
Study 18037095 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 24
Study 16086943 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2082
Study 16086943 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 2082
Study 16086943 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 2082
Study 16086943 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 2082
Study 12383565 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg Hu23F2G (LeukoArrest)
Number of subjects: 420
Study 12383565 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg Hu23F2G (LeukoArrest)
Number of subjects: 420
Study 12383565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 10597847 — intervention group
Group type: EXPERIMENTAL
Intervention: Precooling using cold water immersion for 30 minutes
Number of subjects: 13
Study 10597847 — intervention group
Group type: COMPARATOR
Intervention: Control (no precooling)
Number of subjects: 13
Study 10597847 — intervention group
Group type: EXPERIMENTAL
Intervention: Precooling
Number of subjects: 13
Study 7581059 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial lavage with CEA level measurement in patients with lung cancer (n=84)
Number of subjects: 178
Study 7581059 — intervention group
Group type: COMPARATOR
Intervention: Bronchial lavage in patients with nonmalignant lung disease (n=94)
Number of subjects: 178
Study 7581059 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of CEA levels in lung cancer patients' lavage fluid to serum levels
Number of subjects: 178
Study 2251992 — intervention group
Group type: COMPARATOR
Intervention: Conventional guidewire and low-profile balloons
Number of subjects: 154
Study 2251992 — intervention group
Group type: EXPERIMENTAL
Intervention: New devices (balloon-on-the-wire systems and Omniflex catheter)
Number of subjects: 154
Study 2251992 — intervention group
Group type: EXPERIMENTAL
Intervention: Omniflex catheter
Number of subjects: 154
Study 2251992 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-on-the-wire systems
Number of subjects: 154
Study 2251992 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complication rate
Number of subjects: 154
Study 6997335 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (B) - relaxation instructions and EMG biofeedback
Number of subjects: 27
Study 6997335 — intervention group
Group type: COMPARATOR
Intervention: Instruction-Control (IC) - instructions alone
Number of subjects: 27
Study 6997335 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - no treatment
Number of subjects: 27
Study 31996195 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO-PEN program
Number of subjects: 27
Study 31996195 — intervention group
Group type: COMPARATOR
Intervention: Provision of health insurance
Number of subjects: 27
Study 30992081 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (30 mg elemental zinc)
Number of subjects: 410
Study 30992081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 28402324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (50 μg daily during pregnancy through 6 weeks postpartum)
Number of subjects: 77
Study 28402324 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B12 deficiency in mothers
Number of subjects: 77
Study 28402324 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal folate concentrations
Number of subjects: 77
Study 28402324 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired maternal vitamin B12 status
Number of subjects: 77
Study 25910787 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization of coronary artery calcification and lifestyle recommendations
Number of subjects: 189
Study 25910787 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 189
Study 25910787 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization of coronary artery calcification and lifestyle recommendations (subgroup with statin therapy)
Number of subjects: 189
Study 25910787 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up (subgroup with statin therapy)
Number of subjects: 189
Study 24931252 — intervention group
Group type: EXPERIMENTAL
Intervention: AGEF score tertile (AGEFlow ≤ 0.92, n = 1,006)
Number of subjects: 2998
Study 24931252 — intervention group
Group type: EXPERIMENTAL
Intervention: AGEF score tertile (0.92 < AGEFmid ≤ 1.16, n = 1,000)
Number of subjects: 2998
Study 24931252 — intervention group
Group type: EXPERIMENTAL
Intervention: AGEF score tertile (ACEFhigh > 1.16, n = 992)
Number of subjects: 2998
Study 24931252 — intervention group
Group type: EXPERIMENTAL
Intervention: AGEF score
Number of subjects: 2998
Study 22683672 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus-pertussis vaccine (DTP) administered after measles vaccine
Number of subjects: 455
Study 22683672 — intervention group
Group type: COMPARATOR
Intervention: Control group (male children)
Number of subjects: 455
Study 19950289 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 18
Study 19950289 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 18
Study 17320125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial risk-based prevention programme
Number of subjects: 591
Study 17320125 — intervention group
Group type: COMPARATOR
Intervention: One-time counselling on fall prevention
Number of subjects: 591
Study 15342614 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (Q) 0, 2.5, 10, 25, 50, or 75 mg twice daily with 30 mg Dextromethorphan (DM) for 7 days
Number of subjects: 120
Study 15342614 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (Q) 0, 30, 45, or 60 mg twice daily with 45 or 60 mg DM for 7 days
Number of subjects: 120
Study 15342614 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (Q) 30 mg combined with 30 mg DM every 12 hours for 8 days
Number of subjects: 120
Study 11435884 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary bikunin in stone formers
Number of subjects: 95
Study 11435884 — intervention group
Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 95
Study 11435884 — intervention group
Group type: COMPARATOR
Intervention: Healthy female controls
Number of subjects: 95
Study 11435884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberrant 25 kDa bikunin species in stone formers
Number of subjects: 95
Study 11435884 — intervention group
Group type: COMPARATOR
Intervention: Aberrant 25 kDa bikunin species in healthy controls
Number of subjects: 95
Study 9817126 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the SF‐36 Health Survey
Number of subjects: 321
Study 8042612 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF (5.5 micrograms/kg SC) coadministered with chemotherapy
Number of subjects: 40
Study 8042612 — intervention group
Group type: COMPARATOR
Intervention: Placebo coadministered with chemotherapy
Number of subjects: 40
Study 1676239 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 507
Study 1676239 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 507
Study 655457 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane hypotensive anesthesia (n = 12)
Number of subjects: 30
Study 655457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside hypotensive anesthesia (n = 9)
Number of subjects: 30
Study 655457 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control group (n = 9)
Number of subjects: 30
Study 655457 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 31126674 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency physicians (RQ scores)
Number of subjects: 95
Study 31126674 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency physicians (bias blind spot)
Number of subjects: 95
Study 31126674 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency physicians (representative bias)
Number of subjects: 95
Study 31126674 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (nonphysicians)
Number of subjects: 95
Study 31126674 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency physicians with greater self-reported statistical familiarity
Number of subjects: 95
Study 28752228 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD-ICD (experimental group)
Number of subjects: 378
Study 28752228 — intervention group
Group type: COMPARATOR
Intervention: VVI-ICD (control group)
Number of subjects: 378
Study 28752228 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 378
Study 25465680 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron transdermal system (GTS), one patch on days 1-4
Number of subjects: 276
Study 25465680 — intervention group
Group type: COMPARATOR
Intervention: Intravenous and oral granisetron (control), intravenous on day 1 and oral on days 2-4
Number of subjects: 276
Study 25465680 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron transdermal system (GTS)
Number of subjects: 276
Study 25465680 — intervention group
Group type: COMPARATOR
Intervention: Granisetron transdermal system (GTS) and control
Number of subjects: 276
Study 23535223 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine (16 mg/day)
Number of subjects: 143
Study 23535223 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretic (trichlormethiazide 1 mg/day)
Number of subjects: 143
Study 20951003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrothermally modified starch (HMS)
Number of subjects: 9
Study 20951003 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (MAL)
Number of subjects: 9
Study 19900047 — intervention group
Group type: EXPERIMENTAL
Intervention: O(2) inhalation group (8 l/min oxygen via a facemask for 2 h after delivery)
Number of subjects: 104
Study 19900047 — intervention group
Group type: COMPARATOR
Intervention: Control group (breathed room air in addition to conventional management)
Number of subjects: 104
Study 17442479 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartsaver (HS) training
Number of subjects: 285
Study 17442479 — intervention group
Group type: EXPERIMENTAL
Intervention: Video self-instruction (VSI) training
Number of subjects: 285
Study 17442479 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 285
Study 15730349 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/day)
Number of subjects: 68
Study 15730349 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (1500 mg/day)
Number of subjects: 68
Study 15730349 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg/day) and L-carnitine (500 mg/day) combination
Number of subjects: 68
Study 15730349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 12931807 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited open carpal tunnel release using the Strickland instrumentation (LOCTR)
Number of subjects: 30
Study 12931807 — intervention group
Group type: COMPARATOR
Intervention: Two‐portal endoscopic carpal tunnel release (ECTR)
Number of subjects: 30
Study 10407842 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone substitution therapy
Number of subjects: 28
Study 10407842 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 7473030 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood induction (sad, neutral, happy)
Number of subjects: 0
Study 2344089 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (NS)
Number of subjects: 531
Study 2344089 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% povidone‐iodine solution (PI)
Number of subjects: 531
Study 2344089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pluronic F‐68 (Shur‐Clens) (SC)
Number of subjects: 531
Study 7027925 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of trimethoprim (TMP) per day for 14 days
Number of subjects: 331
Study 7027925 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g of sulfisoxazole (SZ) per day for 14 days
Number of subjects: 331
Study 7027925 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of trimethoprim (TMP) per day for 10 days
Number of subjects: 331
Study 7027925 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g of sulfisoxazole (SZ) per day for 10 days
Number of subjects: 331
Study 16388213 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.1% bupivacaine 10 ml/hour
Number of subjects: 20
Study 16388213 — intervention group
Group type: COMPARATOR
Intervention: Intermittent injection of 0.1% bupivacaine 10 ml hourly
Number of subjects: 20
Study 16388213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 29685164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin + BCG
Number of subjects: 0
Study 29685164 — intervention group
Group type: COMPARATOR
Intervention: Placebo + BCG
Number of subjects: 0
Study 27352070 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive hemodynamic optimization protocol (SG)
Number of subjects: 79
Study 27352070 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (CG)
Number of subjects: 79
Study 24328607 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser-assisted treatment with radial firing tips (RFT2 and RFT3)
Number of subjects: 43
Study 24328607 — intervention group
Group type: COMPARATOR
Intervention: 3% sodium hypochlorite and calcium hydroxide interim dressing (control group)
Number of subjects: 43
Study 22909165 — intervention group
Group type: EXPERIMENTAL
Intervention: 20, 40, 80, or 120 μg of total grass pollen recombinant protein
Number of subjects: 50
Study 22909165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20873125 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 18927527 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Pycnogenol
Number of subjects: 110
Study 18927527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 16275822 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxcarbazepine (60 mg/kg/day)
Number of subjects: 128
Study 16275822 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxcarbazepine (10 mg/kg/day)
Number of subjects: 128
Study 12390816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) plus dexamethasone (10 mg)
Number of subjects: 120
Study 12390816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (3 mg) plus dexamethasone (10 mg)
Number of subjects: 120
Study 12390816 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg)
Number of subjects: 120
Study 12390816 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron (3 mg)
Number of subjects: 120
Study 10532643 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) at a dose of 0.9 mg/kg
Number of subjects: 0
Study 10532643 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with rtPA
Number of subjects: 0
Study 10532643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of rtPA from three trials (NINDS, ECASS I, ECASS II)
Number of subjects: 0
Study 10532643 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of rtPA according to trial protocol
Number of subjects: 0
Study 7752173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 26
Study 7752173 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing
Number of subjects: 26
Study 2265051 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 2 mg kg‐1 in children
Number of subjects: 40
Study 2265051 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 2 mg kg‐1 in infants
Number of subjects: 40
Study 2265051 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium 3-4 mg kg‐1 in infants
Number of subjects: 40
Study 7380822 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 60
Study 7380822 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60
Study 7380822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31795546 — intervention group
Group type: EXPERIMENTAL
Intervention: D-galactose aging model group, subcutaneous injection of D-galactose (500 mg/kg) daily for 6 weeks
Number of subjects: 30
Study 31795546 — intervention group
Group type: COMPARATOR
Intervention: Saline control group, same amount of saline injected for 6 weeks
Number of subjects: 30
Study 31795546 — intervention group
Group type: COMPARATOR
Intervention: Blank control group, no treatment performed
Number of subjects: 30
Study 27885513 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze in a glove finger (Group A)
Number of subjects: 0
Study 27885513 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone packing with airway (Group B)
Number of subjects: 0
Study 27885513 — intervention group
Group type: EXPERIMENTAL
Intervention: Transseptal suture only (Group C)
Number of subjects: 0
Study 27885513 — intervention group
Group type: COMPARATOR
Intervention: No nasal packing (Control)
Number of subjects: 0
Study 24683073 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized feeding progression approaches
Number of subjects: 89
Study 22801471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory cueing, non‐activated wristwatch device and 5 hours of conventional therapy per week (treatment A)
Number of subjects: 8
Study 22801471 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated wristwatch prompting predetermined exercises on the hemiplegic arm for 6 hours daily, 5 days per week for three weeks (treatment B)
Number of subjects: 8
Study 22241313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum‐formed retainers (VFRs)
Number of subjects: 45
Study 22241313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual fixed retainers combined with Hawley retainers (CRs)
Number of subjects: 45
Study 18095278 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin administered at 22:00 h
Number of subjects: 0
Study 18095278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18095278 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous melatonin levels
Number of subjects: 0